Metallothionein levels in ovarian tumours before and after chemotherapy.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108464
Title:
Metallothionein levels in ovarian tumours before and after chemotherapy.
Authors:
Murphy, D; McGown, Alan T; Crowther, Derek; Mander, A; Fox, Brian W
Abstract:
The metallothionein content of ovarian tumours is considerably higher than that found in normal ovaries (greater than 100-fold differences in mean values, P less than 0.001). There was no difference between the metallothionein content of tumours from patients who had completed chemotherapy, usually with a regimen containing a platinum drug, and tumours from untreated patients. Similarly, the level of metallothionein was not influenced by response to therapy, age, stage, histology, or tumour cell differentiation state. These data do not support the hypothesis that metallothionein content is a major determinant of tumour sensitivity in ovarian cancer.
Affiliation:
CRC Department of Medical Oncology, Paterson Institute for Cancer Research, Christie Hospital, Withington, Manchester, UK.
Citation:
Metallothionein levels in ovarian tumours before and after chemotherapy. 1991, 63 (5):711-4 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
May-1991
URI:
http://hdl.handle.net/10541/108464
PubMed ID:
2039697
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorMurphy, Den
dc.contributor.authorMcGown, Alan Ten
dc.contributor.authorCrowther, Dereken
dc.contributor.authorMander, Aen
dc.contributor.authorFox, Brian Wen
dc.date.accessioned2010-07-27T15:53:08Z-
dc.date.available2010-07-27T15:53:08Z-
dc.date.issued1991-05-
dc.identifier.citationMetallothionein levels in ovarian tumours before and after chemotherapy. 1991, 63 (5):711-4 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid2039697-
dc.identifier.urihttp://hdl.handle.net/10541/108464-
dc.description.abstractThe metallothionein content of ovarian tumours is considerably higher than that found in normal ovaries (greater than 100-fold differences in mean values, P less than 0.001). There was no difference between the metallothionein content of tumours from patients who had completed chemotherapy, usually with a regimen containing a platinum drug, and tumours from untreated patients. Similarly, the level of metallothionein was not influenced by response to therapy, age, stage, histology, or tumour cell differentiation state. These data do not support the hypothesis that metallothionein content is a major determinant of tumour sensitivity in ovarian cancer.en
dc.language.isoenen
dc.subjectOvarian Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCarboplatin-
dc.subject.meshCyclophosphamide-
dc.subject.meshDoxorubicin-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshIfosfamide-
dc.subject.meshMelphalan-
dc.subject.meshMetallothionein-
dc.subject.meshMiddle Aged-
dc.subject.meshOvarian Neoplasms-
dc.subject.meshOvary-
dc.titleMetallothionein levels in ovarian tumours before and after chemotherapy.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Paterson Institute for Cancer Research, Christie Hospital, Withington, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.